SHANGHAI, China, Sept. 3 /PRNewswire-FirstCall/ -- Sinobiomed, Inc. ("Sinobiomed", or "the Company") is pleased to announce that Brent Suen has joined the Company as Director of Strategic Development.
Mr. Suen has 18 years of experience in the investment industry both as an investor and as an operator of companies. His career began at Bear Stearns and Co. in 1988 as the youngest hire in the firm's history. During his five-year tenure, he worked in multiple disciplines, including merger arbitrage, trading, sales, and M&A. Having been exposed to different aspects of capital markets, he identified a niche for trading and in 1993 founded and managed Axis Trading Corp. Axis was a pioneer in online trading and execution that is standard practice today. In January 1996, a division of Softbank acquired Axis, reaping a significant return for investors.
From 1997 to 2002, Mr. Suen was a principal in Elevation Capital, a venture capital fund at which he was responsible for identifying technology and biotechnology investments, as well as advising management of investee companies on strategic direction and capital markets activities.
In 2002, Mr. Suen assumed the role of interim CEO of Muse Communications, one of Elevation's portfolio companies. He led Muse through a global product launch and structured a strategic partnership with Fujitsu to integrate Muse into Fujitsu's @Nifty portal.
In early 2003, at the invitation of Muse Communications' angel investors, Mr. Suen relocated to Hong Kong and joined IRG, Limited/IRG TMT Asia Fund. IRG invests in and advises Pan-Asia based technology and biotechnology companies (listed and private) on strategic partnerships, M&A, and capital markets activities. IRG TMT Asia Fund is an investor in Sinobiomed and Brent joined the Company in order to assist in the next phase of growth.
"As Director of Strategic Development, I will actively seek investment in Sinobiomed from both strategic and financial investors, look for opportunistic M&A possibilities and position the Company to become a world class life science company," said Suen.
Banyun Yang, Sinobiomed CEO, said: "We welcome Mr. Suen in an official capacity as Director of Strategic Development. He's been working with us in an unofficial capacity for several months and is also an investor in the Company thru IRG. His activities on our behalf have included the introduction of the Company to Lionel Choong, our new incoming CFO. We anticipate a number of relationships being forged on the funding and strategic partnership side in the near future and look forward with enthusiasm to Mr. Suen's involvement."
ABOUT SINOBIOMED INC.
Sinobiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials and three in research and development. The Company's products respond to a wide range of diseases and conditions, including: malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration. http://www.sinobiomed.com
FORWARD LOOKING STATEMENTS This news release may include "forward-looking statements" regarding Sinobiomed, and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiomed expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiomed does not undertake any obligation to update any forward looking statement, except as required under applicable law.
CONTACT: Sinobiomed Inc., +86-58993708, fax +86-58993709, or investor
relations of Sinobiomed Inc., +1-718-502-8801, toll free, 1-866-588-0829,
info@sinobiomed.com
Web site: http://www.sinobiomed.com/
